Nivolumab vs Gemcitabine or Pegylated Liposomal Doxorubicin: What Regimen Improves Survival in Platinum-Resistant Ovarian Cancer?

September 15, 2021 10:44 am

In a Japanese phase III trial (NINJA) reported in the Journal of Clinical Oncology, Hamanishi et al found that nivolumab did not improve overall survival vs chemotherapy with either gemcitabine or pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer.

Study Read more

NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer

August 30, 2021 5:18 pm

By Hayley Virgil

Updates to the National Comprehensive Cancer Network guidelines on the COVID-19 vaccine for patients with cancer indicate that this group should be prioritized for a third dose.

The National Comprehensive Cancer Network (NCCN) has announced a significant … Read more

Finding cancer earlier: New tests show promise with broader screening available

August 19, 2021 9:33 pm

By Meg Tully

Rosemary Jemo volunteered for a blood test trial based on pioneering research from Johns Hopkins University because she thought it would be great if it could save lives.

The 71-year-old Pennsylvania hairdresser now believes that decision saved … Read more

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumor cells

August 13, 2021 9:27 pm

A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients with breast cancer and other malignancies.… Read more

Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist

August 5, 2021 3:51 pm

By Alan P. Lyss, MD

The COVID-19 pandemic prompted changes to standard practices for cancer clinical trials, and thought leaders have recommended continuing — and improving upon — those new practices.

These recommendations, from members of the American Association for … Read more

Improving Social Needs For Women With Gynecological Cancer Could Improve Outcomes and Lessen Healthcare Disparities

August 4, 2021 4:04 pm

By Ariana Pelosci

Women with gynecologic cancer who experience an improvement of social needs such as companionship and food insecurity could experience improved outcomes.

The identification of social needs and accompanying solutions could result in more actionable health care disparities … Read more

UT Southwestern finds crucial new molecular mechanisms and biomarkers in ovarian cancer

July 30, 2021 4:55 pm

DALLAS – July 30, 2021 – UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments.… Read more

Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors?

July 27, 2021 12:44 pm

For a second time, researchers will test an antibiotic discovered in the 1950s as a potential treatment for cancer.

The first attempt to study the drug, novobiocin, in patients with cancer was a small clinical trial conducted 30 years ago. … Read more

Organ-on-a-Chip Finds Crucial Connection Between Blood and Ovarian Cancers

July 26, 2021 4:48 pm

Researchers at Texas A&M University are pushing organ-on-a-chip devices to new levels that could change the way clinicians approach cancer treatment, particularly ovarian cancer. A team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station.… Read more

Study shows cancer misinformation common on social media sites

July 22, 2021 2:40 pm

A new study published online today in the Journal of the National Cancer Institute reports that one third of the most popular cancer treatment articles on social media contain misinformation. Further, the vast majority of that misinformation has the potential … Read more

Ceralasertib Olaparib Combo Elicits Promising Activity In Parp Resistant Ovarian Cancer

July 15, 2021 2:43 pm

The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.

The combination of ceralasertib and olaparib (Lynparza) induced clinical activity and was well tolerated in … Read more

HIPEC/Carboplatin Does Not Show Significant Results in Ovarian Cancer

July 14, 2021 3:37 pm

By Ariana Pelosci

A new phase 2 study shows that patients who were treated with HIPEC and Carboplatin, did not have better progression-free or overall survival.

Although hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin appeared to be well tolerated in patients … Read more

Virtual biopsies may give more accurate results than traditional method thanks to revolutionary technique

July 11, 2021 3:17 pm

CAMBRIDGE, England — Virtual biopsies could replace invasive tissue procedures and give more accurate results thanks to a revolutionary new method developed using computer scans. The new advanced computing technique uses routine medical scans to enable doctors to take fewer, … Read more

Could a DNA Blood Test Spot a Range of Hidden Cancers?

June 25, 2021 9:14 am

By Alan Mozes

Could a new one-and-done blood test designed to detect as many as 50 different types of cancer become a diagnostic game changer?

Yes, say researchers, who report the method appears accurate and reliable at identifying and locating … Read more

Old Antibiotic Targets BRCA-Mutated, PARP Inhibitor-Resistant Tumors

June 18, 2021 12:21 pm

Studies in laboratory cell lines and in mouse tumor models show an antibiotic developed in the 1950s called novabiocin effectively targets and kills cancer cells with abnormal BRCA1 or BRCA2 genes, which normally help to repair damaged DNA.… Read more

Cancer Patients See High Seroconversion Rates After COVID Vax

June 11, 2021 9:21 am

Dampened responses seen in those with hematological malignancies, however
by Mike Bassett

Patients with cancer who were vaccinated against COVID-19 achieved high seroconversion rates, a single-center study found.

The rate of seroconversion was especially high among patients with solid tumors … Read more

Novel vaccine safe, effective in ovarian cancer subset

June 11, 2021 8:51 am

By Jennifer Southall

A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.… Read more

Universal Genetic Testing Is Far From a Reality in Patients With Ovarian Cancer

June 8, 2021 11:28 am

by Victoria Forster, PhD

Rates of genetic testing in ovarian cancer “remain well below the goal of universal testing,” according to authors of a systematic review and meta-analysis published in Gynecologic Oncology.1Read more

Pafolacianine Sodium, NIRF Imaging Adjunct May Yield Benefit in FR+ Ovarian Cancer

June 8, 2021 11:16 am

Experts reveal pafolacianine sodium may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery, according to a phase 3 study being presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.… Read more